Dexcom Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Morning, everyone. Happy to introduce our next company. We have DexCom's CEO, Kevin Sayer, joining us now. And following up in the Q&A session, we'll also have Jereme Sylvain, the CFO of DexCom.
(Operator Instructions)
But for now, Kevin, I'm going to turn it over to you and join you in a little bit.
Well, Robbie, thanks for having us again this year. We're going to start on Slide 3, and it's a great day for us. I want to start by emphasizing that DexCom still has, and we have tremendous opportunities ahead of us. I've been doing this for a long time with respect to diabetes and the story never changes.
Diabetes continues to grow, be a big problem and it never slows down. And consistently, DexCom has provided the best outcomes and solution across all diabetes. We have a lot of runway left in our U.S. market. While we've achieved a lot of penetration here, there's still plenty of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |